Todd Neale

The guideline specifies that drugs alone are not enough and emphasizes the need for behavioral and lifestyle interventions.

The device may help boost early detection of HFrEF for people living in low-resource settings where echo is scarce.

(UPDATED) The approach is “very exciting,” but one expert says a lot more research is needed, especially around safety, before clinical use.

A caveat to the OPTIMA-AF trial: event rates were much lower than expected, complicating interpretation.

Those who drank the most also had signs of advanced hypertensive cerebral small vessel disease on MRI.

One question, in light of FREEDOM, is how well new DES compare with CABG in patients with diabetes and multivessel disease.

Lower-cost cutting and noncompliant balloons were noninferior to Shockwave IVL for short-term stent outcomes.

Even among light-to-moderate drinkers, cutting back on booze can have a positive effect on blood pressure, researchers showed.

Experts continue to debate whether the health status benefits are real and enough to justify doing the procedures for severe TR.

Polypills for HFrEF are being tested in RCTs, and if they’re approved, experts want to be ready for their rollout and use.